tbuckley/cabot-search huggingface dataset:
POS1345 PULMONARY ARTERY PSEUDOANEURYSMS IN BEHCET’S DISEASE
Authors: O. Jomaa, O. Berriche, S. Arfa, A. Fraj, W. Romdhane, M. Belkhiri, M. Hermassi, R. Makhloufi
Journal: Annals of the Rheumatic Diseases (2021)

Background: Pulmonary artery pseudoaneurysms (PAP) is a serious complication of Behcet’s Disease (BD). Objectives: The aim of this work is to analyze, through 4 observations, the clinical, para-clinical and therapeutic aspects of PAP. Methods: Matériels et méthodes: Retrospective study including 4 cases of PAA among 150 patients who satisfied the criteria of the International Study Group on BD, followed in the Internal Medicine and Radiology Departments at Tahar Sfar Hospital Mahdia TUNISIA. Results: Résultats: Four men, with an average age of 27 years (20-34). PAPs were inaugural, and multiple (&gt;3) in 3 cases and associated with pulmonary embolism in 2 cases. Hemoptysis was the main clinical symptom. All patients were treated with high-dose corticosteroid therapy combined with monthly boluses of cyclophosphamide in addition to colchicine. Two patients had undergone arterial embolization. Surgery was indicated for 2 patients, one of whom died after surgery as a result of massive hemoptysis. The others had a favorable outcome. Conclusion: PAP severity justifies the necessity of early diagnosis and management. The thoracic angio-CT is the imaging of choice for diagnosis. The treatment is based on a corticosteroid therapy and immunosuppressive association with possibly a selective embolization. Disclosure of Interests: None declared
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
Authors: Elizabeth Ahern, Ben J Solomon, Rina Hui, Nick Pavlakis, Ken O'Byrne, Brett G M Hughes
Journal: Journal for ImmunoTherapy of Cancer (2021)

Standard curative treatment of early-stage non-small cell lung cancer (NSCLC) involves surgery in combination with postoperative (adjuvant) platinum-based chemotherapy where indicated. Preoperative (neoadjuvant) therapies offer certain theoretical benefits compared with adjuvant approaches, including the ability to assess on-treatment response, reduce the tumor bulk prior to surgery, and enhance tolerability in the preoperative setting. Indeed, the use of neoadjuvant therapies are well established in other cancers such as breast and rectal cancers to debulk the tumor and guide ongoing therapy, and neoadjuvant chemotherapy has similar efficacy but less toxicity in NSCLC. More recently, immune checkpoint inhibitors (ICI) targeting programmed death-1 (PD1)/PD1-ligand 1 (PD-L1) have transformed the treatment of advanced NSCLC; the unique mechanisms of action of ICI offer additional rationale for assessment in the neoadjuvant setting. Preclinical studies in mouse cancer models support the proof of concept of neoadjuvant ICI (NAICI) through improvement of T-cell effector function and long-term memory induction. Preliminary early-phase human trial data support the proposition that NAICI in NSCLC may provide an feasible and potentially efficacious future treatment strategy and large, randomized phase III trials are currently recruiting to assess this approach. However, outstanding issues include defining optimal treatment combinations which balance high efficacy with acceptable toxicity, validating biomarkers to aid in patient selection, and avoiding potential pitfalls such as missing a window for successful surgery, that is, choosing the right drugs, for the right patient, at the right time. Predictive biomarkers to direct selection of therapy are required, and the validation of major pathological response (MPR) as a surrogate for survival will be important in the uptake of the neoadjuvant approach.
AB0910-HPR LEVELS OF DEPRESSION AND ANXIETY DURING COVID-19 PANDEMIC: AT WHAT DEGREE ARE HEALTH CARE WORKERS AFFECTED IN TUNISIA?
Authors: K. Ben Abdelghani, O. Hamdi, S. Miladi, M. Sellami, K. Ouenniche, L. Souabni, S. Kassab, S. Chekili, A. Fazaa, A. Laatar
Journal: Annals of the Rheumatic Diseases (2021)

Background: Since December 2019, a novel pneumonia caused by coronavirus-19 (COVID-19) has been spreading internationally. Facing this critical pandemic, health care workers who are involved in treating these patients are at risk of developing psychological distress. Objectives: To evaluate mental health outcomes among health care workers treating patients exposed to COVID-19. Methods: This cross-sectional study collected demographic data and mental health measurements from health workers in different hospitals using an online questionnaire. Participants were divided in two groups: G1 included participants working in a COVID-19 unit and G2 included those who worked in a normal ward. Participants were asked to complete the 9-item Patient Health Questionnaire (PHQ-9) and the 7-item Generalized Anxiety Disorder scale (GAD-7). The total scores of these measurement tools were interpreted as follows: PHQ-9 normal (0-4), mild (5-9), moderate (10-14) and severe (15-21) depression; GAD-7 normal (0-4), mild (5-9), moderate (10-14) and severe (15-21) anxiety. We compared the two groups in terms of psychological distress using a Chi-square test. Results: A total of 155 individuals with a mean age of 31.3 ± 25 years [26-45] and a sex-ratio of 0.3 completed the online questionnaire. Seventy-two participants (46%) worked in a COVID-unit. The mean number of nightshifts per month in the COVID-unit was 9.5 in G1 and 1.3 in G2 respectively. The mean number of work hours per day in the COVID unit was 5 hours in G1, and 0 in G2. G2 participants worked in COVID-units during nightshifts only. An increase in workload compared to the pre-epidemic was noted only in G1. Depression and anxiety scores were higher among participants of G1 compared to G2 (Table 1). Table 1. Comparison of the participants according to the PHQ-9 and GAD-7 scores: Score G1 G2 p Mild depression 33% 12% 0.001 Moderate depression 14% 9% 0.000 Severe depression 7% 0.9% 0.002 Mild anxiety 29% 17% 0.005 Moderate anxiety 18% 7.3% 0.002 Severe anxiety 8.4% 2.1% 0.001 G: Group The need for psychological support was more frequent in G1 compared to G2 (38% vs 9%; p=0.005). Participants of G1 were diagnosed with depression (9 cases), anxiety (9 cases) and burn-out (3 cases). In G2, 4 participants were diagnosed with anxiety. The prescribed treatments were: antidepressants (5 cases), anxiolytic (10 cases), and psychotherapy (12 cases). Conclusion: Individuals experience varying levels of distress during pandemics. In our study, health care workers in the frontline of COVID-units experienced high levels of anxiety and depression. Thus, necessary measures should be attached to psychological support strategies for health care workers. Disclosure of Interests: None declared
OP0173 REDUCTION OF SKIN FIBROSIS IN SYSTEMIC SCLEROSIS ON RITUXIMAB TREATMENT. LONG-TERM FOLLOW-UP
Authors: L. Garzanova, L. Ananyeva, O. Koneva, O. Ovsyannikova, O. Desinova, M. Starovoytova, R. Shayakhmetova
Journal: Annals of the Rheumatic Diseases (2021)

Background: A sound experience has been accumulated up to date with the use of rituximab (RTХ) for treatment of systemic sclerosis (SSc). Some studies reported improvement of skin fibrosis following treatment with RTХ, but long-term follow-ups are really few. Objectives: to evaluate the effect of RTХ on the manifestations of skin fibrosis in patients (pts) with SSc in the long-term follow-up. Methods: This prospective study included 71 pts aged 46 years (17-66) on average, 59 (83%) pts were females, mean disease duration was 5,6±4,4 years, and mean follow-up - 42 months (12-72) (mo). Diffuse SSc was established in 42 (59%) pts. All pts received glucocorticoids in low doses. 45% of pts were receiving immunosuppressants at study entry. The following parameters were evaluated: Rodnan skin score (mRSS), interdigital space(IDS) (the distance between the tips of 1 and 5 fingers at maximum extension), oral aperture (OAp) and activity index (EScSG-AI) over the periods: 12-18 mo, 24-30 mo, 36-42 mo, 48-54 mo and 60-72 mo after initiation of RTX therapy. The results are presented as: mean values, delta (Δ), median, upper and lower quartiles. Results: RTX therapy resulted in significant decrease of disease activity index, which statistically significantly correlated with decrease of mRSS - the main indicator of the severity of skin fibrosis (r=0,39;p=0,001). Changes in parameters by follow-up periods are presented in the Table 1. Table 1. Changes in clinical and instrumental parameters at RTX treatment (delta; median; lower quartile; upper quartile). Parameters 12-18 mo (n=71 ) 24-30 mo (n=55 ) 36-42 mo (n=36 ) 48-54 mo (n=24 ) 60-72 mo (n=17 ) ΔmRSS 3,32 [3.3; 0; 8] 5,4 [3; 0; 10] 5,1 [3,5; 0; 9] 5,3 [3; 0; 10] 7,3 [5; 1; 14] p=0,001 p=0,001 p=0,001 p=0,001 p=0,001 ΔOAp, cm 0,24 [0,1; 0; 0,5] 0,26 [0,1; 0; 0,6] 0,39 [0,2; 0; 0,8] 0,31 [0.3; 0; 0,7] 0,36 [0,2; 0; 0,8] p=0,0009 p=0,0006 p=0,004 p=0,006 p=0,009 ΔActivity index (EScSG-AI ) 1,49 [1,5; 0; 2,5] 1,64 [1,5; 0; 2,5] 1,11 [1; 0; 2] 2 [2; 1; 3] 2,17 [2; 1,5; 2] p=0,001 p=0,001 p=0,0001 p=0,0001 p=0,0001 Cumulative dose of RTX, g 1,43±0,6 2,97±0,8 3,45±1,3 3,96±1,1 5,15±1,7 Decreasing of mRSS statistically significantly correlated with increasing cumulative dose of RTX (r=0,29;p=0,01). Decreasing disease activity index correlated with increasing cumulative dose of RTX (r=-0,37; p=0,01). IDS improvement was documented at all assessment time periods, although statistically insignificant. Conclusion: The results of this study confirm reported positive effect of RTX on the reduction of skin fibrosis in SSc. Long-term follow-up demonstrated steadily decreasing skin fibrosis and improvement of microstomia with increasing oral aperture in parallel with a decrease of the disease activity index and increasing cumulative dose of RTX. Disclosure of Interests: None declared
New Editorial Board Member—June 2021
Authors: Melina R. Kibbe
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Dynamic Tremor in a Patient With Parkinson Disease
Authors: Carina França, Kleber Paiva Duarte, Rubens Gisbert Cury
Journal: JAMA Neurology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Time Trends in Use of Radical Prostatectomy by Tumor Risk and Life Expectancy in a National Veterans Affairs Cohort
Authors: Kristina Vaculik, Michael Luu, Lauren E. Howard, William Aronson, Martha Terris, Christopher Kane, Christopher Amling, Matthew Cooperberg, Stephen J. Freedland, Timothy J. Daskivich
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Guidelines endorse using tumor risk and life expectancy (LE) to select appropriate candidates for radical prostatectomy (RP), recommending against treatment of most low-risk tumors and men with limited LE. <h3>Objective</h3> To investigate time trends in the use of RP by tumor risk and Prostate Cancer Comorbidity Index (PCCI) score in a contemporary, nationally representative Veterans Affairs (VA) cohort. <h3>Design, Setting, and Participants</h3> This cohort study of 5736 men treated with RP at 8 VA hospitals from January 1, 2000, to December 31, 2017, used a nationally representative, multicenter sample from the VA SEARCH (Shared Equal Access Regional Cancer Hospital) database. Statistical analysis was performed from June 30, 2018, to August 20, 2020. <h3>Main Outcomes and Measures</h3> Stratified linear and log-linear Poisson regressions were used to estimate time trends in the proportion of men treated with RP across American Urological Association tumor risk and PCCI (a validated predictor of LE based on age and comorbidities) subgroups. <h3>Results</h3> Among 5736 men (mean [SD] age at surgery, 62 [6] years) treated with RP from 2000 to 2017, the proportion of low-risk tumors treated with RP decreased from 51% to 7% (difference, −44%; 95% CI, −50% to −38%). The proportion of intermediate-risk tumors treated with RP increased from 30% to 59% (difference, 29%; 95% CI, 23%-35%), with unfavorable intermediate-risk tumors increasing from 30% to 41% (difference, 11%; 95% CI, 4%-18%) and favorable intermediate-risk tumors decreasing from 61% to 41% (difference, −20%; 95% CI, −24% to −15%). The proportion of high-risk tumors treated with RP increased from 18% to 33% (difference, 15%; 95% CI, 9%-21%). Among men treated with RP, the proportion with the highest PCCI scores of 10 or more (ie, LE &lt;10 years) increased from 4% to 13% (difference, 9%; 95% CI, 4%-14%). Within each tumor risk subgroup, no significant difference in the rate of tumors treated with RP over time was found across PCCI subgroups. <h3>Conclusions and Relevance</h3> In this study, the use of RP shifted from low-risk and favorable intermediate-risk to higher-risk prostate cancer. However, its use among men with limited LE appears unchanged across tumor risk subgroups and increased overall.
Dermatologists’ Perspectives on Artificial Intelligence and Augmented Intelligence — A Cross-sectional Survey
Authors: Caroline A. Nelson, Swapna Pachauri, Rosie Balk, Jeffrey Miller, Rushan Theunis, Justin M. Ko, Carrie L. Kovarik
Journal: JAMA Dermatology (2021)

This cross-sectional survey finds that most dermatologists are receptive to assistance from AI tools and envision a role for augmented intelligence in clinical practice, but they also value the physician-patient relationship and human accuracy.
AB0092 ANTISYNTHETASE SYNDROME: CLINICAL PROFILE, SEROLOGIC AND TREATMENTS USED IN A COHORT OF PATIENTS FOLLOWED AT THE VIRGEN MACARENA HOSPITAL
Authors: P. Muñoz Reinoso, I. García Hernández, M. Ferrer Galván, F. J. Toyos Sáenz de Miera, L. Fernández de la Fuente Bursón, J. J. Pérez Venegas
Journal: Annals of the Rheumatic Diseases (2021)

Background: The antisynthetase syndrome (SAS) is characterized by the presence of antisynthetase antibodies, anti-JO1, PL7 y PL12 are the most common; and the classic triad of myositis, arthritis, and diffuse interstitial lung disease (ILD) 1 . Most patients present incomplete forms and the severity of the ILD determines the prognosis of the disease 2 . Objectives: to analyze epidemiological, clinical and serological characteristics and treatments used in a cohort of patients with SAS. Methods: descriptive study of review of medical records. Data were collected from 15 patients with SAS followed in the Rheumatology and Pneumology consultations of the Virgen Macarena Hospital (Seville) in the last 10 years. The analysis was carried out using the R software. Results: 15 patients were included, 8 men and 7 women. The median age was 56 years (33-77). Seven patients (47%) used to smoke. Four patients (27%) met the classical triad. All of them presented ILD and 8 patients (53%) had arthritis and / or myositis. Five (33%) had mechanic’s hands and six of them (40%) presented Raynaud. Seven (47%) suffered from dyspnea before the SAS diagnosis. The median diagnostic delay was 1 month (0-43). Seven (47%) patients had anti-JO1, 1 (7%) anti-PL7, 2 (13%) anti-PL12 and 2 (13%) patients anti-Ro52. Radiological patterns detected by HRCT were: 5 (33%) NINE, 4 (37%) NIU and 6 (40%) others. The initial treatment included mostly (66%) glucocorticoids (GC) and one or more cFAME. In maintenance, mycophenolate was used in 7 patients (47%), cyclosporine 5 (33%), cyclophosphamide in 3 cases (20%), azathioprine in 3 patients (20%) and methotrexate in 3 of them (20%). Four (37%) patients required a combination of DMARDs and 2 cases needed (13%) biological therapy, Rituximab and Tocilizumab. Changes in the mean value of the initial respiratory function tests (FVC1 and DLCO1) and during follow-up (FVC2 and DLCO2) were not relevant (FVC1 81.5% [42-110], FVC2 81% [59-115]; DLCO1 83% [10-112], DLCO2 80.5% [47-108]). Nine patients (60%) remained clinically stable and 3 patients (20%) progressed radiologically. Four patients died from ILD progression. Conclusion: In this study, the incomplete diagnosis of SAS predominated. The most detected antibody was anti-JO1. ILD is present in all cases, with NINE being the most frequent pattern so multidisciplinary management is necessary. Most used treatments were GC and FAMES combined, some cases required biological therapy. References: [1]Irazoque F, et al. Epidemiology, etiology and classification. Reumatol Clin. 2009;5:2-5. [2]Johnson C, et al. Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type. Respir Med. 2014; 108(10):1542-8. Disclosure of Interests: None declared
Natural discoidal lipoproteins with tiny modification for tumor extracellular dissociation in antitumor chemoimmunotherapy
Authors: Huaqing Zhang, Hao Cheng, Yue Han, Yi Jin, Gang Wang, Chenhua Sun, Wenxin Jiang, Guochen Han, Bo Sun, Zijun Jiang, Zhou Yuan, Jianping Zhou, Yang Ding
Journal: Biomaterials (2021)
Insights into the role of complement regulatory proteins in HPV mediated cervical carcinogenesis
Authors: Asiya Khan, Bhudev C Das, Umme Abiha, Sandeep Sisodiya, Atul Chikara, Sheeraz Un Nazir, Ankan M Das, Alexandre Gomes Rodrigues, Ajit Kumar Passari, Pranay Tanwar, Showket Hussain, Sabia Rashid, Shazia Rashid
Journal: Seminars in Cancer Biology (2021)
Moderate Aortic Stenosis in Patients With Heart Failure and Reduced Ejection Fraction
Authors: Guillaume Jean, Nicolas M Van Mieghem, Tea Gegenava, Lennart van Gils, Jeremy Bernard, Marcel L Geleijnse, E Mara Vollema, Ikram El Azzouzi, Ernest Spitzer, Victoria Delgado, Jeroen J Bax, Philippe Pibarot, Marie-Annick Clavel
Journal: Journal of the American College of Cardiology (2021)
Treatment of Migraine
Authors: John R. Graham
Journal: New England Journal of Medicine (1955)

IN 1933 Critchley1 made the following remarks before the Harveian Society:Migraine has been the happy hunting ground of the theorist, and the problem has been attacked by representatives of all branches of medicine. Each in turn has discovered in migraine phenomena pertaining to his own specialty — has hit upon the true nature of the malady —has found the infallible remedy. Obviously, such mutually exclusive viewpoints cannot all be entirely correct, and the multiplicity and diversity of the hypotheses suggest that the problem is more complex than imagined, and probably one which presents a number of facets.In spite . . .
AB0780 GENDER FEATURES OF VERIFICATION OF DIAGNOSIS UNDIFFERENTIATED ARTHRITIS
Authors: O. Malyshenko, M. Koroleva, M. Letaeva, J. Averkieva, T. Raskina
Journal: Annals of the Rheumatic Diseases (2021)

Background: Undifferentiated arthritis (UDA) is an inflammatory arthritis that does not meet the criteria for any rheumatologic disease. Early verification of UDA is currently one of the main goals of modern rheumatology, since a diagnosis established at an early date allows determining a therapeutic strategy. The high social significance of arthritis lies in the predominant lesion of people of working age, the steady progression of the disease, early disability and a reduction in life expectancy. Objectives: To study the gender characteristics of verification of the diagnosis of undifferentiated arthritis. Methods: A retrospective analysis of 74 case histories of patients diagnosed with UDA was carried out. The study group consisted of 26 men and 48 women, mean age 50.6 ± 4.3 years. All patients underwent a comprehensive laboratory and instrumental examination according to the standard of an articular syndrome of unclear genesis. Results: According to the data obtained, the duration of the articular syndrome averaged 2.53 ± 1.2 years. In 29 patients (21.6% of women and 17.6% of men), on average, after 1.72 ± 0.9 years, the diagnosis of NDA was clarified. Taking into account modern diagnostic criteria, the following diseases were verified: rheumatoid arthritis in 13.5% (12.2% in women and 1.3% in men), ankylosing spondylitis in 10.8% (2.7% in women and 8.1% in men). Osteoarthritis, psoriatic arthritis and APS were diagnosed in 5.4%, 1.4% and 1.4% of women, and gouty arthritis, bone tuberculosis and HIV in 4.1%, 1.4% and 1.4% of men respectively. In 60.8% (43.2% in women and 17.6% in men), the etiology of arthritis was not verified. Conclusion: In a third of patients with UDA, diagnosis verification takes about 2 years on average. In more than half of patients, the diagnosis remains the same. According to the data obtained, rheumatoid arthritis was more often verified in women, while ankylosing spondylitis in men, which is consistent with statistical data. Disclosure of Interests: None declared